Next Generation News and Research

RSS

DuPont and Royal DSM enter joint venture for advanced surgical biomedical materials

DuPont and Royal DSM N.V. announce an agreement to form a joint venture to develop, manufacture and commercialize advanced surgical biomedical materials, pending European Union regulatory approval. The joint venture will be named Actamax Surgical Materials LLC. Under the joint venture agreement, DuPont and DSM will each share a 50 percent interest.

23 Sep 2010

Viking Systems to demonstrate 3DHD Visualization System at Sony's media event

Viking Systems, Inc. announced today its Next Generation 3DHD Visualization System for use in minimally invasive surgery will be prominently featured at Sony's media event to be held September 23, 2010 at Sony's offices in New York, NY. Jed Kennedy, Viking Systems President and CEO and Gerald Andriole, M.D., Medical Advisor to Viking Systems will address the media and explain the features and benefits of the system.

22 Sep 2010

ART closes new $8.5 million venture financing round

Arterial Remodeling Technologies ("ART") announced today that it has closed on a new venture financing round of $8.5 million from existing investors Matignon Technologies and Amundi Private Equity Funds, along with new investor InnoBio Fund managed by CDC Entreprises. Total investment in the Company is now $17 million.

22 Sep 2010

Aeras and Crucell commence Phase II study of TB vaccine candidate in infants

Dutch biopharmaceutical company Crucell N.V. and the Aeras Global TB Vaccine Foundation today announced the start of a Phase II clinical trial in infants of the jointly developed tuberculosis (TB) vaccine candidate, AERAS-402/Crucell Ad35.

22 Sep 2010

ConfiDisc Syringe Injection System granted U.S. patent

Product innovators Chris and Sonia Hillios are pleased to announce that they have been granted a patent by the U.S. Patent and Trademark Office pertaining to their new syringe injection system, ConfiDisc(R).

21 Sep 2010

NIGMS director wins 2011 ASBMB Public Service Award

The American Society for Biochemistry and Molecular Biology has named Jeremy M. Berg, director of the National Institute of General Medical Sciences, the winner of the nonprofit's 2011 ASBMB Howard K. Schachman Public Service Award. Berg will receive the award this evening at an ASBMB Public Affairs Advisory Committee meeting in Arlington, Va.

21 Sep 2010

New professional handbook highlights fast-growing trends in scientific knowledge

As genomic advances reveal new insights into what underlies human health and disease, important questions emerge about the meaning of this information for entire families especially children and their parents. Now, a new professional handbook is available to help researchers, practitioners, and policy makers understand the impacts of these discoveries on child and family well-being.

21 Sep 2010

Six3 gene safeguards future retina

New research led by St. Jude Children's Research Hospital investigators adds to evidence that the Six3 gene functions like a doorman in the developing brain and visual system, safeguarding the future retina by keeping the region where the eye is forming free of a signaling protein capable of disrupting the process.

21 Sep 2010

Seven abstracts on Lantheus' PET imaging candidates to be presented at ASNC2010

Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic medical imaging, today announced that seven abstracts related to two of the company's cardiac Positron Emission Tomography (PET) imaging candidates will be presented at ASNC2010, the 15th Annual Scientific Session of the American Society of Nuclear Cardiology, being held September 23-26, 2010 in Philadelphia.

20 Sep 2010

St. Jude Medical granted European CE Mark for Athena deep brain stimulation therapy management system

St. Jude Medical, Inc., a global medical device company, today announced European CE Mark approval of its new Athena™ programmer, a deep brain stimulation (DBS) therapy management system. This next-generation platform offers clinicians a powerful yet easy-to-use interface that enables them to set or adjust therapeutic parameters to optimize patient results.

20 Sep 2010

Safran to acquire L-1 Identity Solutions' businesses

Safran announced today that it has entered into a definitive agreement with L-1 Identity Solutions, a leading identity management provider in the United States, for Safran to acquire the operating and holding company of L-1 and its biometric and enterprise access solutions, secure credentialing solutions and enrollment services businesses, for a total cash amount of USD 1.09 billion.

20 Sep 2010

CINJ, NJDHSS partner to create Center of Excellence for Cancer Surveillance

A new partnership between The Cancer Institute of New Jersey, the state's only National Cancer Institute -designated Comprehensive Cancer Center, and the New Jersey Department of Health and Senior Services will create a Center of Excellence for Cancer Surveillance to help track, examine, prevent and control cancer. CINJ is a Center of Excellence of the University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School.

18 Sep 2010

USC alumni gift $30 million to South Carolina College of Pharmacy

Two University of South Carolina alumni with a desire to transform pharmacy education and practice are making a $30 million gift to the university's South Carolina College of Pharmacy, the second-largest in the university's history.

18 Sep 2010

HRA Pharma, Watson enter licensing agreement for ulipristal acetate emergency contraceptive commercialization

HRA Pharma, a privately-held, European pharmaceutical company that develops healthcare solutions in reproductive health and endocrinology and makes them available worldwide, and Watson Pharmaceuticals, Inc. announced today that they have entered into a licensing agreement for the commercialization of HRA Pharma's next generation emergency contraceptive ulipristal acetate in Canada.

18 Sep 2010

Elixir Medical commences enrollment in EXCELLA BD trial for DESyne BD Novolimus Eluting CSS

Elixir Medical Corporation, a developer of product platforms that combine innovative medical devices with potent pharmaceuticals for site-specific therapies, announced the initiation of patient enrollment in the EXCELLA BD Randomized Clinical Trial designed to evaluate Elixir's next generation Novolimus Eluting Coronary Stent System (CSS) with bioabsorbable coating, the Elixir DESyne BD Novolimus Eluting CSS.

18 Sep 2010

BARDA awards contract to Emergent BioSolutions for anthrax vaccine development

The U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA) awarded a $51 million contract to Emergent BioSolutions, Inc., of Rockville, Md., for the development of a new anthrax vaccine using the protective antigen (rPA) to stimulate a protective immune response that neutralizes the anthrax toxins.

18 Sep 2010

Boehringer Ingelheim commences afatinib Phase III clinical trial in advanced breast cancer

Boehringer Ingelheim today announced the initiation of a phase III clinical trial to investigate one of its most advanced oncology pipeline compounds, afatinib, for the treatment of patients with advanced (metastatic) breast cancer. Afatinib is an oral compound (taken as a tablet), which is a next generation, targeted therapy, that irreversibly inhibits both, the epidermal growth factor receptor (EGFR/HER1) and the human epidermal receptor HER2, which are involved in tumour growth and spread.

18 Sep 2010

Transition stops TT-223 gastrin analogue combination clinical study in type 2 diabetes

Transition Therapeutics Inc. announced today that a clinical study of gastrin analogue TT-223 in combination with a Lilly proprietary GLP-1 analogue in patients with type 2 diabetes did not meet its efficacy endpoints. Given these findings, there will be no further development of TT-223.

17 Sep 2010

CID to provide update on Cre8 polymer-free DES program at TCT 2010

CID s.r.l., a European company leader in interventional medicine, will update interventional cardiologists on the status of their revolutionary drug eluting stent technology during The Drug Eluting Stent (DES) Summit at TCT 2010, Washington, DC on Wednesday, September 22, 2010. The lecture, entitled "Status of the CID Cre8 polymer-free DES program", will be delivered by Alexandre Abizaid, MD, PhD. Chief of Intervention at Instituto Dante Pazzanese, in Sao Paulo Brazil, and will be part of the session "The Next Generation DES, Polymer-Free".

17 Sep 2010

Biotechnology Institute announces classroom program to improve U.S. life science education quality

Biotechnology industry leaders announced today a major new program to improve the quality of U.S. life science education. The Biotechnology Institute's new "Scientists in the Classroom" initiative is the life science industry's response to President Obama's "Educate to Innovate" campaign to improve the performance of America's students in science, technology, engineering, and mathematics (STEM) education.

17 Sep 2010

Next Generation News and Research

DuPont and Royal DSM enter joint venture for advanced surgical biomedical materials

Viking Systems to demonstrate 3DHD Visualization System at Sony's media event

ART closes new $8.5 million venture financing round

Aeras and Crucell commence Phase II study of TB vaccine candidate in infants

ConfiDisc Syringe Injection System granted U.S. patent

NIGMS director wins 2011 ASBMB Public Service Award

New professional handbook highlights fast-growing trends in scientific knowledge

Six3 gene safeguards future retina

Seven abstracts on Lantheus' PET imaging candidates to be presented at ASNC2010

St. Jude Medical granted European CE Mark for Athena deep brain stimulation therapy management system

Safran to acquire L-1 Identity Solutions' businesses

CINJ, NJDHSS partner to create Center of Excellence for Cancer Surveillance

USC alumni gift $30 million to South Carolina College of Pharmacy

HRA Pharma, Watson enter licensing agreement for ulipristal acetate emergency contraceptive commercialization

Elixir Medical commences enrollment in EXCELLA BD trial for DESyne BD Novolimus Eluting CSS

BARDA awards contract to Emergent BioSolutions for anthrax vaccine development

Boehringer Ingelheim commences afatinib Phase III clinical trial in advanced breast cancer

Transition stops TT-223 gastrin analogue combination clinical study in type 2 diabetes

CID to provide update on Cre8 polymer-free DES program at TCT 2010

Biotechnology Institute announces classroom program to improve U.S. life science education quality

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News